Marta Serafini

This paper develops a humanized ossicle model to track CAR-T cell dynamics and AML progression in real-time, enabling preclinical assessment of immunotherapies.

This study develops a dual CAR-T therapy targeting CD33 and TIM-3 in AML, showing improved specificity and efficacy through glycosylation-modulated TIM-3 recognition.

This study investigates how RANKL inhibition affects bone formation in a mouse model of fibrous dysplasia, finding that bone formation is restricted to specific surfaces rather than occurring diffusely.

This study evaluates the combination of zoledronate and anti-RANKL therapy in a mouse model of fibrous dysplasia, showing delayed disease rebound and improved bone density.